Cost-Sharing Letter Agreement for Diluent Syringe Related to Betaseron® between Chiron Corporation and Schering Berlin Inc.

Contract Categories: Business Operations › Supply Agreements
Summary

Chiron Corporation and Schering Berlin Inc. have agreed to share the additional costs associated with the development and supply of a diluent syringe for Betaseron®. The agreement outlines how costs will be divided between the two companies, depending on whether a new agreement replaces their existing Regulatory Filing, Development and Supply Agreement. The letter also references agreements with third-party suppliers for syringe filling, components, and packaging. Both parties have signed the letter to confirm their understanding and commitment to the cost-sharing arrangement.

Read More Arrow
EX-10.211 4 a2108383zex-10_211.htm EXHIBIT 10.211
QuickLinks -- Click here to rapidly navigate through this document


Exhibit 10.211

REDACTED VERSION

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH
RESPECT TO THE OMITTED PORTIONS.

December 20, 2002

Mr. Lutz Lingnau
President and Chief Executive Officer
Schering Berlin Inc.
340 Changebridge Road
P.O. Box 1000
Montville, NJ 07045-1000
Fax: 973 ###-###-####

Re:
Regulatory Filing, Development and Supply Agreement dated May 10, 1993
between Chiron Corporation and Schering AG (the "RFDS Agreement")

Dear Lutz:

This is to confirm our understanding with respect to cost-sharing for the diluent syringe:

Chiron and Schering have agreed to proceed with a diluent syringe for Betaseron®. In connection therewith, Chiron has negotiated agreements with Baxter for diluent syringe filling, MedNet for the vial adapter component, and PCI for diluent syringe packaging, the key terms of which are set out in an attachment to this letter. Schering and Chiron have agreed to share the incremental costs of the diluent syringe under such agreements as follows: in the event Schering and Chiron sign a new agreement replacing the RFDS Agreement, [***] Schering, [***] Chiron; in the event the parties do not sign such a new agreement, Chiron's share will equal [***] and Schering's share shall [***].

Please sign the enclosed copy of this letter for our records.

        Very truly yours,

        CHIRON CORPORATION

By:   /s/  CRAIG WHEELER      
Craig Wheeler
President, Chiron BioPharmaceuticals		        

Agreed:
 
 

SCHERING BERLIN, INC.
 
 

By:
 
/s/  WOLFGANG KUNZE      
 
 
 
 
    [Signed copy shows strike-through of this name: Lutz Lingnau]
W. Kunze
EVP and CFO


QuickLinks

    Exhibit 10.211